^
    Back
    Association details:
    Biomarker:YES1 amplification
    Cancer:Breast Cancer
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) +
    Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Int J Mol Sci
    Title:

    YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development

    Published date:
    11/26/2021
    Excerpt:
    YES1 was amplified in BT-474-R and further amplified in BT-474-R/TDR (Figure 3A)....In both assays, the combination of T-DM1 with dasatinib was found to be effective in BT-474-R and BT-474-R/TDR....In BT-474-R/TDR, there was no apoptosis with dasatinib alone, but apoptosis was induced by the combination therapy.
    DOI:
    10.3390/ijms222312809